A PYMNTS Company

India: High court questions regulator’s probe against Roche

By  |  May 24, 2017

The Delhi high court on Wednesday observed that an investigation initiated by the Competition Commission of India (CCI) against Roche Products (India) for abuse of dominant position was an ‘interference in the administration of justice’.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    CCI had initiated investigation against Roche and held it to be abusing its position as a market leader resulting in denial of market access to other pharmaceutical companies.

    The regulator’s order was based on written communications by Roche to authorities including the Director Controller General of India (DCGI), National Pharmaceutical Pricing Authority (NPPA) and hospitals/potential buyers discouraging them from buying biosimilar versions of its cancer drug, Trastuzumab sold by its competitors— Mylan and Biocon.

    Full Content: Outlook India

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.